8-K: 10x Genomics Annual Meeting Voting Results

10x Genomics stockholders re-elected three Class I directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Summary

• The 2026 Annual Meeting of stockholders was held on June 4, 2026, with a quorum of approximately 90.5% of eligible votes present.
• Stockholders re-elected Serge Saxonov, Benjamin J. Hindson, and John R. Stuelpnagel as Class I directors for three-year terms.
• Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Executive compensation for named executive officers was approved on a non-binding, advisory basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing that confirms standard corporate governance outcomes without impacting the company's financial or operational trajectory.

Positives

• High voter turnout with approximately 90.5% of eligible votes represented at the meeting.
• Strong shareholder support for the election of all three director nominees.
• Overwhelming ratification of the independent auditor, Ernst & Young LLP.
• Approval of executive compensation packages, indicating shareholder alignment with current management incentives.

Negatives

• None identified in this procedural filing.

Risks

• None identified in this procedural filing.

Future Outlook

The filing does not contain forward-looking financial guidance, focusing exclusively on the results of the annual shareholder meeting.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance procedures for a publicly traded life sciences company, reflecting stability in board composition and auditor relations.

Comparison to Industry Standards

• The voting participation rate of 90.5% is consistent with high-engagement levels seen in large-cap biotechnology and life sciences firms.
• The ratification of a Big Four accounting firm (Ernst & Young) aligns with standard institutional practices for public companies of this size.

Corporate Governance

Stakeholder Impact

• Shareholders maintain continuity in board governance.
• Employees and creditors benefit from the stability of the confirmed auditor and board leadership.

Next Steps

• Directors will serve their three-year terms expiring at the 2029 annual meeting.
• Ernst & Young LLP will proceed with the audit for the fiscal year ending December 31, 2026.

Key Dates

Keywords

10x Genomics, TXG, Annual Meeting, Proxy Voting, Corporate Governance, Shareholder Results